Clinical Trial Update: Evaluation of the Immunogenicity of Vaccination With Multiple Synthetic Melanoma Peptides With Granulocyte-macrophage Colony-stimulating Factor (GM-CSF)-In-Adjuvant, in Patients With Advanced Melanoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the immunogenicity of a melanoma peptide vaccine with GM-CSF adjuvant in patients with advanced melanoma has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) (sargramostim)
• Synthetic Melanoma Peptides Vaccine

Snippet

Sponsor: Craig L Slingluff, Jr | Conditions: Melanoma | Phase 2 | Status: COMPLETED